GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer

Bibliographic Details
Title: GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer
Authors: Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marmé, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Sabine Seiler, Christine Solbach, Sabine Schmatloch, Julia Rey, Sibylle Loibl
Source: npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Publisher Information: Nature Portfolio, 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were randomized 1:1 between idd epirubicin, nab-paclitaxel, and cyclophosphamide (iddEnPC) versus leukocyte nadir-based tailored regimen of dose-dense EC and docetaxel (dtEC-dtD) as adjuvant therapy, with neoadjuvant therapy allowed after amendment. At median follow-up of 6.5 years (overall cohort) and 5.7 years (neoadjuvant cohort, N = 593), both regimens showed comparable 5-year OS rates (iddEnPC 90.8%, dtEC-dtD 90.0%, p = 0.320). In the neoadjuvant setting, iddEnPC yielded a higher pCR rate than dtEC-dtD (51.2% vs. 42.6%, p = 0.045). Patients achieving pCR had significantly improved 5-year iDFS (88.7% vs. 70.1%, HR 0.33, p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2374-4677
Relation: https://doaj.org/toc/2374-4677
DOI: 10.1038/s41523-024-00675-x
Access URL: https://doaj.org/article/b93eb5cc3e364be681372848cc75b63c
Accession Number: edsdoj.b93eb5cc3e364be681372848cc75b63c
Database: Directory of Open Access Journals
More Details
ISSN:23744677
DOI:10.1038/s41523-024-00675-x
Published in:npj Breast Cancer
Language:English